Oncolytics Biotech (ONCY) News
NASDAQ: ONCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.3501-0.0405 (-10.37%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ONCY news summary
We found 15 recent headlines mentioning Oncolytics Biotech (ONCY): 1 in the past week and 11 in the past 30 days, most often from GlobeNewswire, Nasdaq. ONCY is making an outsized move today, down 10.37% at $0.3501, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Oncolytics Biotech Inc. Reports Voting Results from 2026 Annual Meeting", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Oncolytics Biotech headlines
- Oncolytics Biotech Inc. Reports Voting Results from 2026 Annual MeetingOncolytics Biotech Inc. held its 2026 Annual Meeting of Stockholders on November 19, 2026. Stockholders representing 65,061,822, or 49.61%, of the 131,120,719 votes outstanding were represented in…Nasdaq
- Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCACOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal CarciGlobeNewswire
- Oncolytics Biotech Inc. Announces Clinical Supply Agreement with Coherus Oncology, Inc.Oncolytics Biotech Inc. announced that it has entered into a clinical supply agreement with Coherus Oncology, Inc. to evaluate Oncolytics’ investigational oncolytic virus immunotherapy,…NasdaqONCY, WSO.B
- Oncolytics Partners With Coherus For Testing Pelareorep+LOQTORZI Combination In Anal Carcinoma(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Wednesday announced entering a clinical supply agreement with Coherus Oncology Inc. (CHRS) to evaluate the drug…NasdaqCHRS, ONCY, ET
- Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal CarcinomaOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal CarciGlobeNewswire
- Oncolytics Biotech Inc. Announces Translational Data for Pelareorep in Multiple Myeloma to be Presented at 68th ASH Annual MeetingOncolytics Biotech Inc. announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology Annual…Nasdaq
- Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma PatientsPelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma PatientsGlobeNewswire
- Oncolytics Biotech Inc. Announces Translational Data for Pelareorep at SITC 2026 Annual MeetingOncolytics Biotech Inc. announced new translational data from an ongoing study of pelareorep in second-line or later squamous cell anal cancer patients at the Society for Immunotherapy of Cancer 2026…Nasdaq
- Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven CancersTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven CancersGlobeNewswire
- Oncolytics Biotech Inc. Reports Updated Clinical Data from Cohort 4 of GOBLET StudyOncolytics Biotech Inc. announced updated clinical data from Cohort 4 of its Phase 1/2 GOBLET study, which is evaluating pelareorep in combination with atezolizumab in patients with second-line or…NasdaqONCY, BRK.A
- Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven CancersOncolytics announced durability and survival data in anal cancer from GOBLET study, with 100% of responding patients survived for longer than one year.GlobeNewswire
- Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal CancerOncolytics Biotech® Will Present REO 033 Trial in Progress Abstract at ESMO 2026 Showcasing Pelareorep’s Potential in Colorectal CancerGlobeNewswire
- Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentOncolytics Biotech announced updates on the GOBLET Phase 1/2 study and that it will receive final payment under the PanCAN grant this quarter.GlobeNewswire
- Oncolytics Expands Pelareorep Patent Strategy With New Method-of-Use Filings(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, provided an update on its intellectual property strategy, highlighting progress on new method-of-use patent…NasdaqONCY, BRK.A
- Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio UpdateOncolytics extends pelareorep patent protection into the late 2040s while planning new IP for next-generation pelareorep.GlobeNewswire